Clinical Trial Update: FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine [Phase 2]

View source ↗

Summary

This Phase 2 trial in metastatic pancreatic cancer compares first-line therapy with sequential nab-paclitaxel plus gemcitabine followed by FOLFIRI.3 against nab…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Abraxane (nab-paclitaxel) (nab-paclitaxel)
• FOLFIRI.3 regimen (FOLFIRI.3)
• Gemzar (gemcitabine) (gemcitabine)

Snippet

Sponsor: Federation Francophone de Cancerologie Digestive | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-07-09